Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Hematology | Internal Medicine | Oncology | Journal

Back to Journal Articles

Doubling Drug Dose Beneficial in Leukemia Patients

Last Updated: September 23, 2009.

 

Research suggests significant improvement in remission rates and median overall survival

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Doubling the conventional dose of daunorubicin significantly improves complete remission rates and often overall survival in patients with previously untreated acute myeloid leukemia, according to two studies in the Sept. 24 New England Journal of Medicine.

WEDNESDAY, Sept. 23 (HealthDay News) -- Doubling the conventional dose of daunorubicin significantly improves complete remission rates and often overall survival in patients with previously untreated acute myeloid leukemia (AML), according to two studies in the Sept. 24 New England Journal of Medicine.

Bob Lowenberg, M.D., from Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues randomly assigned 813 elderly patients with newly diagnosed AML to cytarabine-based chemotherapy involving daunorubicin at either the conventional dose of 45 mg/m2 or at 90 mg/m2. After a median follow-up of 40 months, they found that patients receiving the higher daunorubicin dose had a higher rate of complete remission, achieved faster than the conventional dose with similar toxicity.

Hugo F. Fernandez, M.D., from the University of South Florida in Tampa, and colleagues randomly assigned 657 adults with untreated AML to cytarabine-based chemotherapy involving daunorubicin at 45 or 90 mg/m2. After a median follow-up of 25.2 months, they found that patients receiving the higher daunorubicin dose had a higher rate of complete remission and median overall survival, with similar toxicity as the conventional dose.

"Do we have a new standard of care in AML?" ask the authors of an accompanying editorial. "The lack of an increase in toxic effects and the benefit in overall survival strongly argue for incorporating high-dose daunorubicin into the initial treatment of younger patients with AML, at least those with favorable- and intermediate-risk cytogenetic profiles, unless an increased rate of toxic effects is feared when high-dose daunorubicin is used in association with new agents, such as FLT3 inhibitors, currently in ongoing trials."

Funding from Wyeth Pharmaceuticals and Immunex was used to perform laboratory correlative studies in the Fernandez study. Both editorial authors reported financial and consulting relationships with pharmaceutical companies.

Abstract - Lowenberg
Full Text (subscription or payment may be required)
Abstract - Fernandez
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Interventions Could Reduce Maternal Mortality in Africa Next: Inactivated Vaccine Worked Best in 2007/2008 Flu Season

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.